Vanguard Fiduciary Trust
LRMR icon

Vanguard Fiduciary Trust’s Larimar Therapeutics LRMR Stock Holding History

Vanguard Fiduciary Trust’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
448,168
+158,536
+55% +$629K ﹤0.01% 2879
2026
Q1 		$1.3M Buy
+289,632
New +$1.16M ﹤0.01% 2791

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Vanguard Fiduciary Trust's LRMR Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Larimar Therapeutics (LRMR) stake by 55% in Q2 2026, buying an estimated $629K and bringing the position to 448,168 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2879.

Vanguard Fiduciary Trust first reported a position in LRMR in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Vanguard Fiduciary Trust held 448,168 shares of Larimar Therapeutics worth $1.37M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 158,536 Larimar Therapeutics shares in Q2 2026, an estimated $629K.
  • Larimar Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2879 holding.
  • Vanguard Fiduciary Trust first reported a position in Larimar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.